Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic treatment for eosinophilic chronic rhinosinusitis with nasal polyps
ACTRN12618000113257Phase 2Active, not recruiting
- Sponsor
- Richard Harvey
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of mepolizumab and dupilumab in chronic rhinosinusitis (CRS), eosinophilic chronic rhinosinusitis (ECRS) and chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Richard Harvey. Primary endpoint: Histopathological eosinophilic count. Started May 2019; status: active, not recruiting.
02
Drugs
mepolizumabdupilumab
03
Conditions
chronic rhinosinusitis (CRS)eosinophilic chronic rhinosinusitis (ECRS)chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ACTRN12618000113257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000113257.